Squarepoint Ops LLC Invests $1.08 Million in Oric Pharmaceuticals, Inc. $ORIC

Squarepoint Ops LLC bought a new stake in shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 106,767 shares of the company’s stock, valued at approximately $1,084,000. Squarepoint Ops LLC owned 0.11% of Oric Pharmaceuticals at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Nisa Investment Advisors LLC boosted its stake in shares of Oric Pharmaceuticals by 17,300.0% during the second quarter. Nisa Investment Advisors LLC now owns 2,436 shares of the company’s stock valued at $25,000 after purchasing an additional 2,422 shares during the period. ANTIPODES PARTNERS Ltd raised its holdings in Oric Pharmaceuticals by 35.9% during the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 5,194 shares of the company’s stock valued at $53,000 after buying an additional 1,372 shares during the last quarter. Creative Planning purchased a new stake in Oric Pharmaceuticals during the 2nd quarter valued at $113,000. Tower Research Capital LLC TRC grew its holdings in Oric Pharmaceuticals by 1,293.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,757 shares of the company’s stock worth $119,000 after acquiring an additional 10,913 shares during the last quarter. Finally, CWM LLC increased its position in shares of Oric Pharmaceuticals by 303.0% in the second quarter. CWM LLC now owns 12,457 shares of the company’s stock valued at $126,000 after acquiring an additional 9,366 shares during the period. 95.05% of the stock is owned by hedge funds and other institutional investors.

Oric Pharmaceuticals Price Performance

Shares of Oric Pharmaceuticals stock opened at $8.04 on Monday. Oric Pharmaceuticals, Inc. has a 1 year low of $3.90 and a 1 year high of $14.93. The firm has a market cap of $783.02 million, a price-to-earnings ratio of -4.65 and a beta of 1.32. The company has a 50-day moving average of $11.71 and a 200 day moving average of $10.98.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.08. On average, equities analysts anticipate that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current year.

Insider Buying and Selling at Oric Pharmaceuticals

In other Oric Pharmaceuticals news, insider Pratik S. Multani sold 10,720 shares of the business’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $9.06, for a total value of $97,123.20. Following the sale, the insider directly owned 68,149 shares of the company’s stock, valued at approximately $617,429.94. The trade was a 13.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Jacob Chacko sold 53,001 shares of the stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $12.05, for a total value of $638,662.05. Following the completion of the sale, the chief executive officer directly owned 568,880 shares in the company, valued at approximately $6,855,004. This represents a 8.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 190,814 shares of company stock worth $2,171,318. 5.55% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on ORIC shares. HC Wainwright increased their target price on shares of Oric Pharmaceuticals from $19.00 to $23.00 and gave the stock a “buy” rating in a report on Friday, November 14th. Wolfe Research assumed coverage on Oric Pharmaceuticals in a report on Tuesday, November 18th. They issued a “peer perform” rating for the company. Guggenheim initiated coverage on Oric Pharmaceuticals in a research note on Thursday, September 4th. They set a “buy” rating and a $18.00 target price on the stock. JPMorgan Chase & Co. raised their price target on Oric Pharmaceuticals from $17.00 to $20.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Wednesday, October 8th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $19.67.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.